PFM Health Sciences LP lessened its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 10.3% during the first quarter, HoldingsChannel.com reports. The fund owned 204,344 shares of the company’s stock after selling 23,532 shares during the period. PFM Health Sciences LP’s holdings in Guardant Health were worth $31,193,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the stock. Valeo Financial Advisors LLC grew its stake in Guardant Health by 4.6% in the 1st quarter. Valeo Financial Advisors LLC now owns 1,702 shares of the company’s stock worth $260,000 after buying an additional 75 shares in the last quarter. American International Group Inc. grew its stake in Guardant Health by 4.9% in the 4th quarter. American International Group Inc. now owns 2,062 shares of the company’s stock worth $266,000 after buying an additional 97 shares in the last quarter. Prudential Financial Inc. grew its stake in Guardant Health by 0.3% in the 1st quarter. Prudential Financial Inc. now owns 40,099 shares of the company’s stock worth $6,121,000 after buying an additional 128 shares in the last quarter. Fifth Third Bancorp grew its stake in Guardant Health by 7.2% in the 1st quarter. Fifth Third Bancorp now owns 2,061 shares of the company’s stock worth $315,000 after buying an additional 139 shares in the last quarter. Finally, Dynamic Advisor Solutions LLC grew its stake in Guardant Health by 4.1% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 3,689 shares of the company’s stock worth $563,000 after buying an additional 145 shares in the last quarter. 89.55% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:GH traded down $0.08 during midday trading on Thursday, reaching $119.13. 5,829 shares of the stock traded hands, compared to its average volume of 875,038. The company has a quick ratio of 20.99, a current ratio of 21.29 and a debt-to-equity ratio of 1.34. Guardant Health, Inc. has a 12 month low of $77.69 and a 12 month high of $181.07. The firm has a market capitalization of $12.05 billion, a PE ratio of -35.46 and a beta of 0.51. The business has a fifty day moving average of $120.42.
GH has been the subject of a number of research reports. SVB Leerink reissued a “buy” rating on shares of Guardant Health in a research note on Sunday, May 23rd. Raymond James assumed coverage on shares of Guardant Health in a research note on Tuesday, June 15th. They issued a “market perform” rating for the company. Zacks Investment Research raised shares of Guardant Health from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Wells Fargo & Company upped their price objective on shares of Guardant Health from $145.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, June 21st. Finally, William Blair reaffirmed a “buy” rating on shares of Guardant Health in a research note on Thursday, May 27th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $165.15.
In related news, Director Stanley J. Meresman sold 4,934 shares of the stock in a transaction dated Monday, July 12th. The shares were sold at an average price of $124.27, for a total value of $613,148.18. Following the completion of the transaction, the director now directly owns 8,993 shares in the company, valued at approximately $1,117,560.11. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Helmy Eltoukhy sold 751 shares of the stock in a transaction dated Monday, April 26th. The stock was sold at an average price of $160.01, for a total transaction of $120,167.51. Following the completion of the transaction, the chief executive officer now owns 1,828,514 shares of the company’s stock, valued at $292,580,525.14. The disclosure for this sale can be found here. Insiders sold a total of 34,104 shares of company stock valued at $4,745,511 over the last 90 days. Company insiders own 5.80% of the company’s stock.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.
Further Reading: What is the CAC 40 Index?
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.